JOHNSON & JOHNSON — Director's Dealing 2022

Dec 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2022-11-30

Reporting Person: McEvoy Ashley (EVP, WW Chair, MedTech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-30	Common Stock	M	73323.0000	$72.5400	Acquired	115135.9545	Direct
2022-11-30	Common Stock	S	1400.0000	$176.0923	Disposed	113735.9545	Direct
2022-11-30	Common Stock	S	71923.0000	$175.4553	Disposed	41812.9545	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-30	Employee Stock Options (Right to Buy)	$72.5400	M	73323.0000	Disposed	2023-01-13	Common Stock (73323.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2695.0000	Indirect
Common Stock	300.0000	Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $176.050 to $176.115. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $175.040 to $176.010. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)

F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)